Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease.

Redmond EM, Guha S, Walls D, Cahill PA.

Expert Opin Investig Drugs. 2011 Dec;20(12):1649-64. doi: 10.1517/13543784.2011.628658. Epub 2011 Oct 18. Review.

2.

Doubling down with inhibitors of Notch and Hedgehog signaling pathways.

Weiss GJ.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S409-10. doi: 10.1097/JTO.0b013e31826df2cd. Review. No abstract available.

3.

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

J├Ąger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D.

Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27. No abstract available.

PMID:
28004600
4.

Notch signaling: an emerging therapeutic target for cancer treatment.

Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K.

Cancer Lett. 2015 Dec 1;369(1):20-7. doi: 10.1016/j.canlet.2015.07.048. Epub 2015 Sep 1. Review.

5.

Notch inhibitors as a new tool in the war on cancer: a pathway to watch.

Purow B.

Curr Pharm Biotechnol. 2009 Feb;10(2):154-60. Review.

6.

Rational targeting of Notch signaling in cancer.

Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L.

Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226. Review.

PMID:
18758481
7.

Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic.

Laranjeira AB, Yang SX.

Expert Opin Drug Discov. 2016 Nov;11(11):1071-1080. Epub 2016 Sep 25. Review.

PMID:
27626707
8.

Emerging from their burrow: Hedgehog pathway inhibitors for cancer.

Gan GN, Jimeno A.

Expert Opin Investig Drugs. 2016 Oct;25(10):1153-66. doi: 10.1080/13543784.2016.1216973. Epub 2016 Aug 5. Review.

PMID:
27459882
9.

Targeting the Hedgehog and Notch signaling pathways.

Weiss GJ.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1820-1. doi: 10.1097/01.JTO.0000407572.67949.06. No abstract available.

10.

Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.

Banerjee U, Hadden MK.

Expert Opin Drug Discov. 2014 Jul;9(7):751-71. doi: 10.1517/17460441.2014.920817. Epub 2014 May 22. Review.

PMID:
24850423
11.

Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells.

Okuhashi Y, Itoh M, Nara N, Tohda S.

Anticancer Res. 2011 Mar;31(3):893-6.

PMID:
21498710
12.

Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition.

Cohen DJ.

Hematol Oncol Clin North Am. 2012 Jun;26(3):565-88, viii. doi: 10.1016/j.hoc.2012.01.005. Review.

PMID:
22520980
13.

Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis.

Beyer C, Dees C, Distler JH.

Arch Dermatol Res. 2013 Jan;305(1):1-8. doi: 10.1007/s00403-012-1304-7. Epub 2012 Dec 4. Review.

PMID:
23208311
14.

Hedgehog inhibitors: a patent review (2013 - present).

Xin M.

Expert Opin Ther Pat. 2015 May;25(5):549-65. doi: 10.1517/13543776.2015.1019864. Epub 2015 Mar 1. Review.

PMID:
25726713
15.

Development of anticancer agents targeting the Hedgehog signaling.

Zhang X, Tian Y, Yang Y, Hao J.

Cell Mol Life Sci. 2017 Aug;74(15):2773-2782. doi: 10.1007/s00018-017-2497-x. Epub 2017 Mar 17. Review.

PMID:
28314894
16.

Notch inhibitors for cancer treatment.

Espinoza I, Miele L.

Pharmacol Ther. 2013 Aug;139(2):95-110. doi: 10.1016/j.pharmthera.2013.02.003. Epub 2013 Feb 28. Review.

17.

Hedgehog signaling pathway and cancer therapeutics: progress to date.

Ruch JM, Kim EJ.

Drugs. 2013 May;73(7):613-23. doi: 10.1007/s40265-013-0045-z. Review.

PMID:
23605693
18.

Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability.

Distler A, Lang V, Del Vecchio T, Huang J, Zhang Y, Beyer C, Lin NY, Palumbo-Zerr K, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2014 Jun;73(6):1264-8. doi: 10.1136/annrheumdis-2013-204221. Epub 2014 Jan 20.

PMID:
24445254
19.

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

Brechbiel J, Miller-Moslin K, Adjei AA.

Cancer Treat Rev. 2014 Jul;40(6):750-9. doi: 10.1016/j.ctrv.2014.02.003. Epub 2014 Feb 24. Review.

PMID:
24613036
20.

NOTCH signaling as a novel cancer therapeutic target.

Miele L, Miao H, Nickoloff BJ.

Curr Cancer Drug Targets. 2006 Jun;6(4):313-23. Review.

PMID:
16848722

Supplemental Content

Support Center